AnteoTech completes initial CLIA development program and advances commercial relationship
AnteoTech (ASX: ADO) has completed, on schedule, the initial stage of a collaborative immunoassay product development program that commenced in March 2026, and has agreed to progress to the next stage of work.
The program is focused on developing AnteoBind™ NXT activated magnetic particles for the global chemiluminescent immunoassay (CLIA) market. The counterparty is described only as a large global Life Sciences company, with its identity not disclosed at this stage of the commercial relationship.
AnteoTech recognised A$61,595 in revenue from the program in FY2026. The completion represents a strategic milestone supporting the company’s CLIA market-entry and broader commercialisation strategy.
When big ASX news breaks, our subscribers know first
Inside the milestone: what was completed
The Initial Work Program involved performance testing of AnteoBind™ NXT activated magnetic particles to assess their suitability for use in large scale, high-throughput, automated CLIA diagnostic platforms. The magnetic particles were supplied by the large global Life Sciences company.
The next stage of work has been agreed and is about to commence. According to AnteoTech, it includes in-house work from the counterparty’s side as well as support for the company’s Kit launch by way of bead supply.
The CLIA development partnership announced in March 2026 marked the beginning of this collaboration, with technical milestones set as preconditions before progressing to a joint product development agreement and formal market entry.
In March 2026, AnteoTech released a CLIA White Paper outlining broader AnteoBind™ NXT magnetic particle activation studies, which demonstrated several performance and cost advantages over conventional bioconjugation chemistries:
-
Up to six times lower capture antibody usage
-
Up to six times faster activation
-
Improved assay performance
The cost dimension is notable, as capture antibodies can account for up to 35% of total assay costs.
Merrill Gray, Managing Director & CEO
“It is great that this initial collaborative CLIA product development work program has been completed successfully and on schedule. During program interactions I have seen the Life Sciences team strengthen AnteoTech’s customer relationship. We have now agreed on the next steps with the large Life Sciences company, and these include in-house work from their side and support for our Kit launch, by way of bead supply.”
Understanding the CLIA market opportunity
Chemiluminescent immunoassays (CLIA) have become a cornerstone technology in clinical diagnostics. They enable the detection and quantification of hormones, infectious disease markers, cardiac biomarkers and tumour markers.
Their high sensitivity, broad dynamic range and compatibility with automated laboratory platforms have made them one of the fastest-growing immunoassay technologies globally. Within this market, performance improvement and cost reduction are critical priorities for both researchers and procurement teams.
Activated magnetic particles play an important role here, delivering the performance required by today’s high-throughput, fully automated CLIA platforms used in clinical laboratories worldwide. AnteoTech’s proprietary AnteoBind™ NXT surface chemistry aims to address customer needs by improving antibody orientation, enhancing assay performance while reducing antibody consumption.
For investors, the market context is meaningful. Successful entry into the CLIA market would almost double the addressable immunoassay markets AnteoTech currently participates in.
| Market segment | Value (2024) | Growth outlook |
|---|---|---|
| Global IVD market | ~US$100B+ | ~7% CAGR to 2029 |
| Immunoassays market | US$56B (65% of global IVD) | ~9% CAGR to 2029 |
| CLIA market | ~US$13B | ~6% CAGR to 2029 |
| Magnetic particles segment | US$21B | ~5% CAGR to 2029 |
Moving up the diagnostics value chain
AnteoTech’s broader Life Sciences strategy is to move further up the diagnostic value chain. This involves evolving from a supplier of an enabling chemistry to a provider of higher-value products, including ready-to-use CLIA Kits and optimised activation protocols.
According to the company, this approach increases its commercial relevance to customers while expanding the value captured from each customer relationship.
The new CLIA Kit reflects this direction. It combines magnetic beads sourced from selected suppliers with AnteoBind™ NXT activation chemicals, the corresponding buffers and optimised activation protocols, supporting the company’s commercialisation strategy through higher-value combined and optimised products.
ADLM 2026 launch and go-to-market pathway
AnteoTech will launch its new CLIA Kit at ADLM 2026 in Anaheim, California, between 26–30 July 2026, one of the world’s leading diagnostics and laboratory medicine conferences.
The company will also showcase its AnteoBind™ product portfolio across Lateral Flow, Luminex and ELISA applications, engaging with existing and prospective customers, distribution partners and potential commercial collaborators. Customer outreach is well underway, with meetings scheduled throughout the conference.
Alongside the launch, AnteoTech has commenced a pilot “go to market” strategy:
-
Assessing potential market entry pathways, including regional distribution partners, activated magnetic particle suppliers and contract kit assembly partners.
-
Leveraging relationships established through Austrade and its distribution partners in South Korea, Japan and India to evaluate regional opportunities.
-
Prioritising the most attractive market entry pathways, with further updates to be provided as assessments progress.
Merrill Gray, Managing Director & CEO
“This is an important strategic step for AnteoTech as it moves us further up the diagnostics value chain, evolving from supplying enabling chemicals to providing combined and optimised higher-value, ready-to-use products simplifying customer testing and adoption. […] Establishing demand for our new CLIA Kits in potential pilot markets is underway so we can develop detailed ‘go to market’ plans.”
The successful completion of the Initial Work Program, together with agreement to progress to the next stage, represents an important milestone towards establishing a broader joint product development collaboration in the CLIA market with well-established partners.
Don’t Miss the Next Healthcare Breakthrough on ASX
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis already done for you. Join 20,000+ subscribers staying ahead of the market on ASX biotech and diagnostics. Click the “Free Alerts” button at StockWire X to start receiving alerts the moment news breaks.